Physician profile
Laura L Perrin
NPI 1316967599
$3,510.11
in general payments reported to CMS, 2019-2025
22 companies · $513 in 2025
The $513 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $270 · 2021: $682 · 2022: $801 · 2023: $571 · 2024: $226 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,310.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $678.18 | 2019-2025 | Cequa |
| Alcon Vision LLC | $619.54 | 2019-2025 | Total30, Precision7, Tryptyr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $337.41 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $317.06 | 2022-2025 | Vyzulta, Infuse, Miebo |
| Johnson & Johnson Vision Care, INC. | $274.69 | 2020-2025 | |
| Coopervision INC. | $210.20 | 2019-2025 | Misight Contact Lens, Clariti Contact Lens, Myday Contact Lens |
| Novartis Pharmaceuticals Corporation | $162.29 | 2019-2022 | |
| Glaukos Corporation | $153.07 | 2023 | |
| Biotissue Holdings INC. | $110.76 | 2025 | |
| Kala Pharmaceuticals, INC. | $110.25 | 2021-2022 | |
| Allergan, INC. | $81.08 | 2020-2021 | |
| Oyster Point Pharma, INC. | $76.50 | 2022-2024 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $74.20 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $52.43 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $51.68 | 2022-2025 | Oxervate |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $49.55 | 2025 | Vevye |
| Sight Sciences, INC. | $42.50 | 2023-2024 | Tearcare System |
| Ocular Therapeutix, INC. | $30.17 | 2022-2023 | Dextenza |
| Abbvie INC. | $28.57 | 2022 | |
| Maculogix, INC. | $20.67 | 2019 | |
| Alimera Sciences, INC. | $15.00 | 2019 | |
| Horizon Therapeutics Plc | $14.31 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Perrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.